The company will not receive any proceeds from the sale of the shares by the selling stockholder.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Seres Therapeutics Streamlines Focus with VOWST Sale to Nestlé
- Seres shareholders request clarity from board about possible Nestle offer
- Seres Therapeutics shareholders approve sale of VOWST
- Seres Therapeutics’ SER-155 Shows Promising Clinical Results
- Seres Therapeutics reports data from Cohort 2 of SER-155 Phase 1b study